Equities analysts forecast that TearLab Corp (NASDAQ:TEAR) will announce earnings per share of ($0.72) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for TearLab Corp’s earnings. The highest EPS estimate is ($0.69) and the lowest is ($0.78). TearLab Corp posted earnings per share of ($1.00) in the same quarter last year, which suggests a positive year-over-year growth rate of 28%. The company is expected to announce its next earnings results on Wednesday, August 2nd.

On average, analysts expect that TearLab Corp will report full-year earnings of ($2.79) per share for the current financial year, with EPS estimates ranging from ($3.01) to ($2.62). For the next year, analysts expect that the business will report earnings of ($1.39) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for TearLab Corp.

TearLab Corp (NASDAQ:TEAR) last posted its quarterly earnings data on Monday, May 15th. The medical research company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $7.02 million. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.21) earnings per share.

TEAR has been the topic of a number of recent analyst reports. Rodman & Renshaw restated a “buy” rating and set a $12.00 target price on shares of TearLab Corp in a report on Friday, March 10th. Zacks Investment Research upgraded shares of TearLab Corp from a “sell” rating to a “hold” rating in a report on Thursday, March 16th. Craig Hallum set a $6.00 target price on shares of TearLab Corp and gave the stock a “buy” rating in a report on Saturday, March 11th. Feltl & Co. downgraded shares of TearLab Corp from a “strong-buy” rating to a “buy” rating and set a $9.00 target price on the stock. in a report on Saturday, March 11th. Finally, HC Wainwright set a $12.00 target price on shares of TearLab Corp and gave the stock a “buy” rating in a report on Sunday, March 12th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. TearLab Corp has an average rating of “Buy” and an average price target of $5.05.

TearLab Corp (NASDAQ:TEAR) traded down 9.30% during mid-day trading on Wednesday, hitting $1.95. 76,287 shares of the company traded hands. The company’s 50-day moving average is $2.34 and its 200-day moving average is $4.47. TearLab Corp has a one year low of $1.85 and a one year high of $9.00. The stock’s market capitalization is $10.47 million.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/05/17/0-72-earnings-per-share-expected-for-tearlab-corp-tear-this-quarter.html.

In other TearLab Corp news, major shareholder Awm Investment Company, Inc. sold 327,674 shares of the company’s stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $3.20, for a total value of $1,048,556.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 11.60% of the stock is owned by insiders.

An institutional investor recently raised its position in TearLab Corp stock. AWM Investment Company Inc. increased its stake in shares of TearLab Corp (NASDAQ:TEAR) by 37.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,277,250 shares of the medical research company’s stock after buying an additional 2,000,000 shares during the period. AWM Investment Company Inc. owned about 13.76% of TearLab Corp worth $4,730,000 as of its most recent SEC filing. Institutional investors and hedge funds own 36.09% of the company’s stock.

TearLab Corp Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

5 Day Chart for NASDAQ:TEAR

Get a free copy of the Zacks research report on TearLab Corp (TEAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TearLab Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corp and related companies with MarketBeat.com's FREE daily email newsletter.